Sign in or create an account to add this stock to your watchlist.
About Spectrum Pharmaceuticals (NASDAQ:SPPI)
Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for peripheral T-cell lymphoma (PTCL); ZEVALIN injection for patients with B-cell non-Hodgkin's lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing POZIOTINIB for treating breast and lung cancer; ROLONTIS for chemotherapy-induced neutropenia; and QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. The company sells its drugs through group purchasing organizations, wholesalers, and directly in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:SPPI
CUSIP84763A10
Phone702-835-6300
Debt
Debt-to-Equity RatioN/A
Current Ratio2.97
Quick Ratio2.91
Price-To-Earnings
Trailing P/E Ratio-17.53
Forward P/E Ratio-20.62
P/E GrowthN/A
Sales & Book Value
Annual Sales$128.37 million
Price / Sales15.21
Cash FlowN/A
Price / CashN/A
Book Value$3.12 per share
Price / Book6.01
Profitability
EPS (Most Recent Fiscal Year)($1.07)
Net Income$-91,240,000.00
Net Margins-64.39%
Return on Equity-29.47%
Return on Assets-19.00%
Miscellaneous
Employees215
Outstanding Shares104,060,000
Spectrum Pharmaceuticals (NASDAQ:SPPI) Frequently Asked Questions
What is Spectrum Pharmaceuticals' stock symbol?
Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI."
How were Spectrum Pharmaceuticals' earnings last quarter?
Spectrum Pharmaceuticals (NASDAQ:SPPI) announced its earnings results on Thursday, May, 3rd. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.19. The biotechnology company earned $30.50 million during the quarter, compared to analysts' expectations of $25.68 million. Spectrum Pharmaceuticals had a negative return on equity of 29.47% and a negative net margin of 64.39%. The business's revenue was up 4.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.14) EPS. View Spectrum Pharmaceuticals' Earnings History.
What price target have analysts set for SPPI?
4 analysts have issued 12-month target prices for Spectrum Pharmaceuticals' shares. Their forecasts range from $25.00 to $33.00. On average, they expect Spectrum Pharmaceuticals' share price to reach $29.00 in the next twelve months. View Analyst Ratings for Spectrum Pharmaceuticals.
Are investors shorting Spectrum Pharmaceuticals?
Spectrum Pharmaceuticals saw a increase in short interest in the month of April. As of April 13th, there was short interest totalling 11,563,282 shares, an increase of 12.4% from the March 30th total of 10,288,002 shares. Based on an average trading volume of 3,296,568 shares, the short-interest ratio is currently 3.5 days. Currently, 12.3% of the company's stock are short sold.
Who are some of Spectrum Pharmaceuticals' key competitors?
Some companies that are related to Spectrum Pharmaceuticals include Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), Catalent (CTLT), Agios Pharmaceuticals (AGIO), Loxo Oncology (LOXO), Dr. Reddy's Laboratories (RDY), Taro Pharmaceutical Industries (TARO), United Therapeutics (UTHR), GW Pharmaceuticals (GWPH), FibroGen (FGEN) and Ligand Pharmaceuticals (LGND).
Who are Spectrum Pharmaceuticals' key executives?
Spectrum Pharmaceuticals' management team includes the folowing people:
- Mr. Joseph W. Turgeon, Pres, CEO & Director (Age 60)
- Mr. Kurt A. Gustafson, Exec. VP & CFO (Age 50)
- Mr. Thomas J. Riga, Exec. VP, COO & Chief Commercial Officer (Age 42)
- Mr. Shivpreet Kapoor, VP of Strategic Planning & Investor Relations
- Mr. Keith McGahan, Sr. VP & Chief Legal Officer
Has Spectrum Pharmaceuticals been receiving favorable news coverage?
Media headlines about SPPI stock have trended somewhat positive on Sunday, Accern Sentiment reports. The research firm identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Spectrum Pharmaceuticals earned a news sentiment score of 0.04 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 48.39 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Spectrum Pharmaceuticals' major shareholders?
Spectrum Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.48%),
SHROTRIYA RAJESH C MD
(5.92%), Dimensional Fund Advisors LP (2.32%), Northern Trust Corp (1.04%), Wells Fargo & Company MN (0.99%) and Principal Financial Group Inc. (0.69%). Company insiders that own Spectrum Pharmaceuticals stock include Joseph W Turgeon, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner and Thomas J Riga. View Institutional Ownership Trends for Spectrum Pharmaceuticals.
Which institutional investors are selling Spectrum Pharmaceuticals stock?
SPPI stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Dimensional Fund Advisors LP, ClariVest Asset Management LLC, California Public Employees Retirement System, Royal Bank of Canada, American International Group Inc., Public Employees Retirement Association of Colorado and State of Tennessee Treasury Department. Company insiders that have sold Spectrum Pharmaceuticals company stock in the last year include Joseph W Turgeon, Kurt A Gustafson, Rajesh C Md Shrotriya, Stuart Mitchell Krassner and Thomas J Riga. View Insider Buying and Selling for Spectrum Pharmaceuticals.
Which institutional investors are buying Spectrum Pharmaceuticals stock?
SPPI stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, UBS Group AG, BNP Paribas Arbitrage SA, DekaBank Deutsche Girozentrale, Wells Fargo & Company MN, Iguana Healthcare Management LLC, Harvey Partners LLC and Mackay Shields LLC. View Insider Buying and Selling for Spectrum Pharmaceuticals.
How do I buy shares of Spectrum Pharmaceuticals?
Shares of SPPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Spectrum Pharmaceuticals' stock price today?
One share of SPPI stock can currently be purchased for approximately $18.76.
How big of a company is Spectrum Pharmaceuticals?
Spectrum Pharmaceuticals has a market capitalization of $1.95 billion and generates $128.37 million in revenue each year. The biotechnology company earns $-91,240,000.00 in net income (profit) each year or ($1.07) on an earnings per share basis. Spectrum Pharmaceuticals employs 215 workers across the globe.
How can I contact Spectrum Pharmaceuticals?
Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The biotechnology company can be reached via phone at 702-835-6300 or via email at [email protected]
MarketBeat Community Rating for Spectrum Pharmaceuticals (SPPI)
MarketBeat's community ratings are surveys of what our community members think about Spectrum Pharmaceuticals and other stocks. Vote "Outperform" if you believe SPPI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SPPI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Spectrum Pharmaceuticals (NASDAQ:SPPI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Spectrum Pharmaceuticals in the last 12 months. Their average twelve-month price target is $29.00, suggesting that the stock has a possible upside of 54.58%. The high price target for SPPI is $33.00 and the low price target for SPPI is $25.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $29.00 | $29.00 | $25.40 | $24.25 |
| Price Target Upside: | 54.58% upside | 31.82% upside | 15.45% upside | 26.11% upside |
Spectrum Pharmaceuticals (NASDAQ:SPPI) Consensus Price Target History
Spectrum Pharmaceuticals (NASDAQ:SPPI) Analyst Ratings History
Show:
(Data available from 5/27/2016 forward)
Spectrum Pharmaceuticals (NASDAQ:SPPI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 12/11/2012 | special | $0.15 | | 12/18/2012 | 12/20/2012 | 12/28/2012 |
(Data available from 1/1/2013 forward)
Spectrum Pharmaceuticals (NASDAQ SPPI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 9.35%
Institutional Ownership Percentage: 77.11%
Spectrum Pharmaceuticals (NASDAQ SPPI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/17/2018 | Stuart Mitchell Krassner | Director | Sell | 21,113 | $18.94 | $399,880.22 | 57,944 |  |
| 5/14/2018 | Rajesh C Md Shrotriya | Director | Sell | 24,014 | $18.38 | $441,377.32 | 200,652 | |
| 5/14/2018 | Thomas J Riga | COO | Sell | 3,290 | $18.10 | $59,549.00 | | |
| 5/11/2018 | Rajesh C Md Shrotriya | Director | Sell | 30,000 | $17.55 | $526,500.00 | 200,652 | |
| 5/9/2018 | Rajesh C Md Shrotriya | Director | Sell | 30,000 | $16.21 | $486,300.00 | 200,652 | |
| 5/7/2018 | Rajesh C Md Shrotriya | Director | Sell | 30,000 | $15.98 | $479,400.00 | 200,652 | |
| 5/4/2018 | Rajesh C Md Shrotriya | Director | Sell | 90,000 | $16.28 | $1,465,200.00 | 200,652 | |
| 5/1/2018 | Rajesh C Md Shrotriya | Director | Sell | 90,000 | $16.43 | $1,478,700.00 | 200,652 | |
| 4/27/2018 | Rajesh C Md Shrotriya | Director | Sell | 30,000 | $17.17 | $515,100.00 | 200,652 | |
| 4/25/2018 | Rajesh C Md Shrotriya | Director | Sell | 30,000 | $17.26 | $517,800.00 | 200,652 | |
| 4/23/2018 | Rajesh C Md Shrotriya | Director | Sell | 30,000 | $18.37 | $551,100.00 | 200,652 | |
| 4/20/2018 | Rajesh C Md Shrotriya | Director | Sell | 30,000 | $18.67 | $560,100.00 | 200,652 | |
| 4/18/2018 | Rajesh C Md Shrotriya | Director | Sell | 90,000 | $19.00 | $1,710,000.00 | 200,652 | |
| 4/17/2018 | Joseph W Turgeon | CEO | Sell | 11,565 | $19.00 | $219,735.00 | 316,509 | |
| 4/16/2018 | Rajesh C Md Shrotriya | Director | Sell | 30,000 | $18.72 | $561,600.00 | 200,652 | |
| 4/16/2018 | Thomas J Riga | COO | Sell | 3,900 | $18.60 | $72,540.00 | 254,694 | |
| 4/13/2018 | Rajesh C Md Shrotriya | Director | Sell | 30,000 | $19.93 | $597,900.00 | 200,652 | |
| 4/11/2018 | Rajesh C Md Shrotriya | Director | Sell | 30,000 | $20.30 | $609,000.00 | 200,652 | |
| 4/9/2018 | Rajesh C Md Shrotriya | Director | Sell | 12,300 | $15.01 | $184,623.00 | 200,652 | |
| 4/6/2018 | Rajesh C Md Shrotriya | Director | Sell | 3,686 | $15.00 | $55,290.00 | 200,652 | |
| 4/4/2018 | Rajesh C Md Shrotriya | Director | Sell | 30,000 | $15.01 | $450,300.00 | 200,652 | |
| 4/2/2018 | Rajesh C Md Shrotriya | Director | Sell | 60,000 | $15.90 | $954,000.00 | 200,652 | |
| 4/2/2018 | Thomas J Riga | COO | Sell | 1,948 | $15.58 | $30,349.84 | 256,452 | |
| 3/28/2018 | Joseph W Turgeon | CEO | Sell | 4,810 | $16.40 | $78,884.00 | 328,074 | |
| 3/28/2018 | Kurt A Gustafson | CFO | Sell | 4,350 | $16.35 | $71,122.50 | 187,193 | |
| 3/28/2018 | Rajesh C Md Shrotriya | Director | Sell | 90,000 | $16.88 | $1,519,200.00 | 200,652 | |
| 3/26/2018 | Kurt A Gustafson | CFO | Sell | 1,300 | $17.38 | $22,594.00 | 191,543 | |
| 3/26/2018 | Rajesh C Md Shrotriya | Director | Sell | 30,000 | $17.34 | $520,200.00 | 200,652 | |
| 3/26/2018 | Thomas J Riga | COO | Sell | 220 | $17.41 | $3,830.20 | 251,476 | |
| 3/22/2018 | Joseph W Turgeon | CEO | Sell | 3,100 | $18.17 | $56,327.00 | 332,884 | |
| 3/22/2018 | Kurt A Gustafson | CFO | Sell | 2,640 | $18.13 | $47,863.20 | 192,843 | |
| 3/21/2018 | Stuart Mitchell Krassner | Director | Sell | 4,200 | $18.64 | $78,288.00 | 83,257 | |
| 2/5/2013 | Anthony E Maida III | Director | Sell | 5,000 | $12.25 | $61,250.00 | | |
| 11/12/2012 | Joseph Kenneth Keller | COO | Buy | 10,000 | $10.95 | $109,500.00 | | |
| 11/1/2012 | Anthony E Maida III | Director | Sell | 5,000 | $11.09 | $55,450.00 | | |
| 9/4/2012 | Anthony E Maida III | Director | Sell | 5,000 | $12.01 | $60,050.00 | | |
(Data available from 1/1/2013 forward)
Spectrum Pharmaceuticals (NASDAQ SPPI) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Free Research Reports on Sorrento Therapeutics and Three More Biotech Stocks
finance.yahoo.com - May 25 at 8:16 AM |
 | $28.03 Million in Sales Expected for Spectrum Pharmaceuticals (SPPI) This Quarter
www.americanbankingnews.com - May 25 at 4:18 AM |
| Zacks: Brokerages Expect Spectrum Pharmaceuticals (SPPI) Will Announce Earnings of -$0.18 Per Share
www.americanbankingnews.com - May 23 at 11:20 AM |
| Spectrum Pharmaceuticals (SPPI) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 21 at 5:33 PM |
 | OncoMed Pharmaceuticals: Assessing The Prospect Of A Potential Robust Winner
seekingalpha.com - May 21 at 8:14 AM |
| Spectrum Pharmaceuticals (SPPI) Director Sells $399,880.22 in Stock
www.americanbankingnews.com - May 18 at 7:53 PM |
| Spectrum Pharma up 17% on late-stage Rolontis data
seekingalpha.com - May 17 at 6:46 PM |
 | Why Spectrum Pharmaceuticals, Inc. Is Up Big Today
www.fool.com - May 17 at 1:40 PM |
 | Spectrum Pharma (SPPI) Highlights Detailed Results from Phase 3 Study of ROLONTIS (eflapegrastim) Published in ASCO Abstract
www.streetinsider.com - May 17 at 8:19 AM |
| CORRECTING and REPLACING Spectrum Pharmaceuticals Announces Detailed Results from Phase 3 Study of ROLONTIS® (eflapegrastim) Published in an ASCO Abstract
finance.yahoo.com - May 17 at 8:19 AM |
| Spectrum Pharmaceuticals (SPPI) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - May 15 at 2:09 PM |
| Spectrum Pharmaceuticals (SPPI) COO Thomas J. Riga Sells 3,290 Shares
www.americanbankingnews.com - May 14 at 8:16 PM |
| Rajesh C. Md Shrotriya Sells 30,000 Shares of Spectrum Pharmaceuticals (SPPI) Stock
www.americanbankingnews.com - May 14 at 4:15 PM |
| Insider Selling: Spectrum Pharmaceuticals (SPPI) Director Sells 24,014 Shares of Stock
www.americanbankingnews.com - May 14 at 4:15 PM |
| Zacks Investment Research Lowers Spectrum Pharmaceuticals (SPPI) to Hold
www.americanbankingnews.com - May 14 at 12:13 PM |
| Spectrum Pharmaceuticals (SPPI) Upgraded to "Sell" by BidaskClub
www.americanbankingnews.com - May 11 at 8:53 PM |
| Spectrum Pharmaceuticals (SPPI) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - May 9 at 6:47 PM |
| Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2018 Health Care Conference on May 16th
finance.yahoo.com - May 9 at 8:16 AM |
| Zacks Investment Research Downgrades Spectrum Pharmaceuticals (SPPI) to Sell
www.americanbankingnews.com - May 7 at 1:13 PM |
| Blog Exposure - Spectrum Pharma Inked Licensing Agreement with The University of Texas MD Anderson Cancer Center on Certain Methods of Use of Poziotinib
finance.yahoo.com - May 7 at 8:18 AM |
| Spectrum Pharmaceuticals (SPPI) Expected to Post Quarterly Sales of $27.55 Million
www.americanbankingnews.com - May 7 at 1:58 AM |
| -$0.21 EPS Expected for Spectrum Pharmaceuticals (SPPI) This Quarter
www.americanbankingnews.com - May 5 at 11:14 PM |
| Spectrum Pharmaceuticals (SPPI) Posts Quarterly Earnings Results, Beats Estimates By $0.19 EPS
www.americanbankingnews.com - May 4 at 5:55 PM |
| Insider Selling: Spectrum Pharmaceuticals (SPPI) Director Sells 90,000 Shares of Stock
www.americanbankingnews.com - May 4 at 4:37 PM |
| Spectrum Pharmaceuticals' (SPPI) CEO Joe Turgeon on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 4 at 8:17 AM |
| Edited Transcript of SPPI earnings conference call or presentation 3-May-18 8:30pm GMT
finance.yahoo.com - May 4 at 8:17 AM |
| Spectrum Pharmaceuticals beats by $0.20, beats on revenue
seekingalpha.com - May 3 at 5:26 PM |
| Spectrum Pharma in-licenses IP related to certain uses of poziotinib
seekingalpha.com - May 3 at 5:26 PM |
| Spectrum Pharma: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 5:26 PM |
| Spectrum Pharmaceuticals Reports First Quarter 2018 Financial Results and Pipeline Update
finance.yahoo.com - May 3 at 5:26 PM |
| Spectrum Pharmaceuticals Announces Exclusive Licensing Agreement on Certain Methods of Use of Poziotinib with The University of Texas MD Anderson Cancer Center
finance.yahoo.com - May 3 at 8:13 AM |
| Spectrum Pharmaceuticals (SPPI) to Release Earnings on Thursday
www.americanbankingnews.com - May 2 at 8:10 PM |
| Spectrum Pharmaceuticals (SPPI) Upgraded to Strong-Buy at ValuEngine
www.americanbankingnews.com - May 2 at 6:06 PM |
| Spectrum Pharmaceuticals (SPPI) Lowered to "Strong Sell" at BidaskClub
www.americanbankingnews.com - May 2 at 12:02 PM |
| Spectrum Pharmaceuticals (SPPI) Director Rajesh C. Md Shrotriya Sells 90,000 Shares
www.americanbankingnews.com - May 1 at 7:18 PM |
| Insider Selling: Spectrum Pharmaceuticals (SPPI) Director Sells 30,000 Shares of Stock
www.americanbankingnews.com - May 1 at 7:18 PM |
 | Thermo Fisher Scientific Signs New Agreements to Expand Oncomine Dx Target Test
www.prnewswire.com - May 1 at 8:22 AM |
 | Spectrum Pharmaceuticals Enters into a Next-Generation Sequencing Companion Diagnostic Partnership with Thermo ...
www.businesswire.com - May 1 at 8:22 AM |
 | BRIEF-Spectrum Pharmaceuticals Enters Into A Next-Generation Sequencing Companion Diagnostic Partnership With ...
www.reuters.com - May 1 at 8:22 AM |
| Spectrum Pharma rescinds poison pill provision, reshuffles board; shares down 4%
seekingalpha.com - April 30 at 5:15 PM |
| Spectrum Pharmaceuticals Announces Corporate Governance Enhancements and Board Changes
finance.yahoo.com - April 30 at 8:21 AM |
| Spectrum Pharmaceuticals (SPPI) Short Interest Update
www.americanbankingnews.com - April 27 at 3:42 AM |
| Spectrum Pharmaceuticals (SPPI) Director Rajesh C. Md Shrotriya Sells 30,000 Shares
www.americanbankingnews.com - April 26 at 7:12 PM |
| Spectrum Pharmaceuticals (SPPI) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 26 at 5:36 PM |
| Spectrum Pharmaceuticals Announces First Quarter 2018 Financial Results Teleconference and Webcast
finance.yahoo.com - April 26 at 8:15 AM |
| Form 4 SPECTRUM PHARMACEUTICALS For: Apr 19 Filed by: SHROTRIYA RAJESH C MD
www.streetinsider.com - April 24 at 8:18 AM |
| Spectrum Pharma (SPPI) Reports Publication of Poziotinib Data
www.streetinsider.com - April 24 at 8:18 AM |
| Zacks: Analysts Anticipate Spectrum Pharmaceuticals (SPPI) Will Announce Quarterly Sales of $26.10 Million
www.americanbankingnews.com - April 20 at 1:06 AM |
| Spectrum Pharma (SPPI) Highlights Data Showing Poziotinib Overcomes De Novo Resistance of HER2 Exon 20 Insertion Mutations in NSCLC and Other Cancers
www.streetinsider.com - April 19 at 8:13 AM |
| Brokerages Anticipate Spectrum Pharmaceuticals (SPPI) to Post -$0.24 EPS
www.americanbankingnews.com - April 18 at 11:22 PM |
Spectrum Pharmaceuticals (NASDAQ:SPPI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Spectrum Pharmaceuticals (NASDAQ:SPPI) Income Statement, Balance Sheet and Cash Flow Statement
Spectrum Pharmaceuticals (NASDAQ SPPI) Stock Chart for Sunday, May, 27, 2018
Loading chart…
